Drug Profile
Imsidolimab - AnaptysBio
Alternative Names: ANB 019Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator AnaptysBio
- Class Anti-inflammatories; Antibodies; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 36 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pustular psoriasis
Highest Development Phases
- Phase III Generalised pustular psoriasis
- Phase II Acneiform eruptions; Ichthyosis
- No development reported Palmoplantar pustulosis
- Discontinued Acne vulgaris; Hidradenitis suppurativa
Most Recent Events
- 12 Apr 2024 AnaptysBio has patent protection for imsidolimab in various countries, as of December 2023 (AnaptysBio, Form 10-K)
- 12 Apr 2024 AnaptysBio has patents pending for imsidolimab in various countries, as of December 2023 (AnaptysBio, Form 10-K)
- 09 Oct 2023 AnaptysBio plans to file a biologics license application (BLA) for Generalized Pustular Psoriasis with the US FDA by Q3 2024.